ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 380
A New Tool to Assess Muscle Strength in Polymyositis and Dermatomyositis: Hand-Held Dynamometry
9:00AM-11:00AM
Abstract Number: 376
Antisynthetase Syndrome: Prevalence of Serositis in Autoantibody Subsets
9:00AM-11:00AM
Abstract Number: 392
Autoantibody Profile and Clinical Characteristics in Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 396
Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 388
Comparison of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme Α Reductase and Anti-Signal Recognition Particle Necrotising Myopathies: A Single Centre Experience
9:00AM-11:00AM
Abstract Number: 386
Differences in Body Composition in Myositis Patients and Healthy Controls Are Associated with Disease Activity and Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
9:00AM-11:00AM
Abstract Number: 394
In Patients with Suspected Idiopathic Inflammatory Myopathy, Does Pre-Biopsy Musculoskeletal MRI Result in Greater Yield of Diagnostic Biopsy Results? Summary of Data from a 10-Year Single Hospital Audit
9:00AM-11:00AM
Abstract Number: 387
Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis
9:00AM-11:00AM
Abstract Number: 381
Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores
9:00AM-11:00AM
Abstract Number: 383
Myositis Patients with Anti-U1-RNP and Anti-Ro52 Autoantibodies Are at Risk of Pericarditis, Glomerulonephritis, and Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 397
Myositis-Specific Autoantibodies and Their Clinical Associations
9:00AM-11:00AM
Abstract Number: 382
Nailfold Capillary Changes in the Adult Newly Onset-Dermatomyositis: A Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 374
Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different?
9:00AM-11:00AM
Abstract Number: 375
Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”
9:00AM-11:00AM
Abstract Number: 384
Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 393
Physical Activity Monitoring Using Wrist-Worn Accelerometer in the Assessment and Follow-up of Patients with Myositis
9:00AM-11:00AM
Abstract Number: 377
Preliminary Validation of Rectus Femoris Muscle Ultrasound in Idiopathic Inflammatory Myopathy Patients
9:00AM-11:00AM
Abstract Number: 378
Pulmonary Hypertension in Anti-Synthetase Syndrome
9:00AM-11:00AM
Abstract Number: 389
Risk Factors Associated with Mortality in Inflammatory Myositis: An Asian Perspective
9:00AM-11:00AM
Abstract Number: 379
Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 390
Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI
9:00AM-11:00AM
Abstract Number: 385
Sexual Dysfunction in Female Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 395
Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
9:00AM-11:00AM
Abstract Number: 373
The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology